查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014348

慢性阻塞性肺病（COPD）治療市場：依產品、給藥途徑、通路及最終用戶分類－2026年至2032年全球市場預測

Chronic Obstructive Pulmonary Disease Therapeutics Market by Product, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，慢性阻塞性肺病(COPD) 治療市場價值將達到 234.1 億美元，到 2026 年將成長至 251.6 億美元，到 2032 年將達到 391.6 億美元，複合年成長率為 7.62%。

主要市場統計數據
基準年 2025 234.1億美元
預計年份：2026年 251.6億美元
預測年份 2032 391.6億美元
複合年成長率 (%) 7.62%

對 COPD（慢性阻塞性肺病）護理的臨床複雜性、治療方法演變、醫療設備創新和相關人員優先事項進行全面的背景概述。

慢性阻塞性肺病（COPD）仍然是一個複雜的臨床和商業性挑戰，需要製藥公司、醫療設備製造商、臨床醫生和政策制定者共同應對。治療格局已從單一氣管擴張劑療法發展到針對不同疾病表現型的聯合治療療法和標靶治療。隨著臨床實務中對發炎特徵和急性惡化風險多樣性的認知不斷加深，治療決策正從統一的方案轉向更個人化的策略，以平衡症狀控制、預防急性惡化和長期肺功能維持。

分析美國在 2025 年實施的關稅措施將如何重塑 COPD 治療的整體供應鏈、籌資策略、臨床供應連續性和定價優勢。

美國進口關稅和貿易政策的變化可能會對整個慢性阻塞性肺病（COPD）治療生態系統產生連鎖反應，改變活性成分、特殊添加劑、醫療設備組件和成品吸入器的採購成本結構。當某些原料的關稅提高時，製造商將面臨更高的接收成本，並被迫重新評估其供應鏈設計。因此，採購團隊通常會採取措施來減輕跨境關稅波動的影響，例如供應商多角化、盡可能增加在地採購採購，或與位於需求點附近的契約製造（CMO）合作。

透過整合產品分類、給藥途徑、通路和最終用戶情況等方面的細分洞察，我們推動有針對性的商業化和臨床引入。

精細的市場區隔方法能夠從產品分類、給藥途徑、分銷管道和終端用戶環境等方面提供可操作的洞察，這些因素共同決定了產品的定位和商業化策略。在以產品為基礎的市場區隔中，支氣管擴張劑仍然是緩解症狀的基礎，而長效支氣管擴張劑與吸入性皮質類固醇和其他藥物的複方製劑則有助於更全面地管理氣流阻塞和降低病情加重風險。抗生素則用於治療感染疾病引起的病情加重，而祛痰藥可以改善某些患者的痰液排放。為了最大限度地發揮治療價值，應對這些差異需要不同的證據收集策略和患者支持模式。

區域洞察重點在於全球主要地區的獨特法規結構、支付方趨勢、製造能力和病患就醫現狀。

區域趨勢持續對策略產生重大影響，涵蓋監管路徑、病患取得途徑以及醫療設備偏好等各個面向。在美洲，報銷機制以及品牌藥和非專利藥的競爭格局推動了檢驗的給藥技術和數位化用藥依從性支援工具的快速普及，同時，支付方的嚴格審查也要求突破性創新必須提供強力的衛生經濟學證據。在歐洲、中東和非洲（EMEA），監管方式的多樣性和報銷環境的差異性有利於靈活的打入市場策略，這些策略將本地夥伴關係與區域特定的定價和准入計劃相結合。在這些地區，器械的便利性和成本效益往往是採購決策中的重要考量。

這份策略性企業趨勢回顧說明了製造商和醫療設備合作夥伴如何協調開發、合作和證據生成，以在 COPD 治療產品領域中脫穎而出。

領先的製藥和醫療設備公司正在調整其產品組合和夥伴關係關係，以實現慢性阻塞性肺病（COPD）治療領域的臨床差異化和營運效率。常見的策略重點包括推進器材-藥物混合平台的發展，投資真實世界數據（REW）舉措以驗證常規臨床實踐中的治療效果，以及與數位醫療公司合作，將藥物依從性和吸入支持整合到產品價值提案中。隨著企業尋求擴充性且符合品質標準的生產系統，以滿足醫療設備複雜的組裝和供應需求，契約製造和專業吸入器供應商的重要性日益凸顯。

為行業領導者提供切實可行的優先建議，以協調產品設計、證據產生、供應鏈韌性、支付方參與和患者支援。

產業領導者應採取平衡策略，將臨床差異化與可擴展的商業性可行性結合。首先，應優先選擇能夠直接解決藥物依從性和吸入技術實際應用障礙的設備和製劑，強調直覺的設計、清晰的使用說明以及整合的數位監測功能，從而幫助臨床醫生獲得可操作的見解。同時，應投資於有針對性的證據生成，將傳統的臨床終點和患者報告結局（PRO）與衛生經濟學模型相結合，以直接解決支付方對長期價值的擔憂。

高度透明的調查方法，詳細說明了與關鍵相關人員的互動、二手文獻的整合、監管和專利資訊的整合以及專家檢驗過程。

本報告的研究採用結構化、多維度的方法，整合了來自一手和二手調查的證據。一手調查包括對臨床醫生、呼吸科護士、醫院藥劑師、支付方和行業高管的定性訪談，旨在了解處方因素、設備偏好和推廣障礙等方面的實際觀點。此外，報告還與監管和報銷專家進行了有針對性的諮詢，以揭示跨區域的核准途徑和支付方的決策標準。

結論強調，整合臨床差異化、醫療設備創新、證據產生和供應鏈敏捷性對於持續成功至關重要。

總而言之，慢性阻塞性肺病（COPD）的治療格局呈現出臨床細微差別、醫療設備進步和不斷演變的醫療服務模式交匯融合的特點，所有這些都要求採取綜合性的策略性應對措施。相關人員科學創新與以患者為中心的器械設計、可靠的真實世界數據和穩健的供應鏈相結合的利益相關者，將更有能力應對醫保審查和競爭壓力。從以產品為中心的模式轉向以綜合護理解決方案為核心的治療價值提案，將醫療服務體系、數位化支援和醫護人員教育融入其中，將有助於加速產品應用並改善治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：慢性阻塞性肺病（COPD）治療市場：依產品分類

  • 抗生素
  • 支氣管擴張劑
  • 組合藥物
  • 皮質類固醇
  • 祛痰藥

第9章：慢性阻塞性肺病（COPD）治療市場：依給藥途徑分類

  • 吸入
    • 乾粉吸入器
    • 定量噴霧吸入器
    • 噴霧器
  • 注射藥物
  • 口服

第10章：慢性阻塞性肺病（COPD）治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：慢性阻塞性肺病（COPD）治療市場：依最終使用者分類

  • 診所
  • 居家醫療
  • 醫院

第12章：慢性阻塞性肺病（COPD）治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：慢性阻塞性肺病（COPD）治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章慢性阻塞性肺病（COPD）治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國慢性阻塞性肺病（COPD）治療市場

第16章：中國慢性阻塞性肺病（COPD）治療藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Almirall SA
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • Cipla Limited
  • CSL Limited
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Mylan NV
  • Novartis AG
  • Orion Corporation
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Theravance Biopharma, Inc.
  • Verona Pharma plc
  • Yuhan Corporation
Product Code: MRR-4311CE1A3394

The Chronic Obstructive Pulmonary Disease Therapeutics Market was valued at USD 23.41 billion in 2025 and is projected to grow to USD 25.16 billion in 2026, with a CAGR of 7.62%, reaching USD 39.16 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 23.41 billion
Estimated Year [2026] USD 25.16 billion
Forecast Year [2032] USD 39.16 billion
CAGR (%) 7.62%

Comprehensive contextual introduction outlining clinical complexity, therapeutic evolution, device innovation, and stakeholder priorities in COPD care delivery

Chronic obstructive pulmonary disease remains a complex clinical and commercial challenge that demands coordinated responses from drug developers, device manufacturers, clinicians, and policy makers. The therapeutic landscape has matured from single-agent bronchodilation toward combination regimens and targeted interventions that address heterogeneous disease phenotypes. As clinical practice increasingly recognizes variations in inflammatory profiles and exacerbation risk, therapeutic decision making has moved beyond one-size-fits-all protocols and toward more individualized strategies that balance symptomatic control, exacerbation prevention, and long-term lung function preservation.

Given the centrality of inhalation as a route of administration and the emergence of novel biologic and small molecule candidates, stakeholders must manage competing priorities: optimizing delivery technology, improving adherence, and demonstrating value to payers and health systems. Transitional trends such as expanded homecare, telehealth-enabled monitoring, and heightened scrutiny of antimicrobial stewardship further complicate care pathways. Consequently, organizations need a clear, integrated view of clinical drivers, device innovations, regulatory dynamics, and commercial levers to translate research and development investments into measurable improvements in patient outcomes.

The COPD paradigm is entering a transformative phase characterized by converging technological, scientific, and service delivery innovations that redefine clinical practice and commercial strategy. Precision approaches to patient phenotyping, including biomarkers and eosinophil-guided therapy selection, are shifting treatment algorithms toward targeted anti-inflammatory therapy for selected patient subsets. At the same time, digital health solutions for inhaler monitoring and adherence support are accelerating, enabling real-world data capture and more meaningful measures of treatment impact beyond traditional endpoints.

In parallel, device innovation continues to influence therapeutic performance and patient acceptance; the refinement of dry powder inhaler mechanisms, reformulation of pressurized metered dose inhalers to minimize propellant impact, and improvements in nebulizer efficiency are all reshaping delivery choices. Service delivery is also evolving, with a greater emphasis on homecare models, remote monitoring, and integrated care pathways that reduce hospital readmissions and streamline chronic disease management. Taken together, these shifts are compelling manufacturers to align product development, patient support programs, and evidence generation strategies to remain competitive in a landscape that prizes both clinical differentiation and operational scalability.

Analysis of how evolving United States tariff measures in twenty twenty five could realign supply chains, procurement strategies, clinical supply continuity, and pricing levers across COPD therapeutics

Changes in import tariffs and trade policies that take effect in the United States can have ripple effects throughout the COPD therapeutics ecosystem by altering the economics of sourcing active pharmaceutical ingredients, specialized excipients, device components, and finished combination inhalers. When tariffs increase on specific inputs, manufacturers face higher landed costs that incentivize re-evaluation of supply chain design. Consequently, procurement teams often respond by diversifying suppliers, increasing local content where feasible, or engaging contract manufacturing organizations closer to demand centers to reduce exposure to cross-border tariff volatility.

Moreover, tariffs can influence formulation and device decisions when cost pressures make certain delivery platforms relatively more expensive. Clinical trial supply chains also feel pressure; sponsors may prioritize local sourcing for critical study materials to avoid delays and customs-related risk. From a payer and provider perspective, any sustained increase in cost can alter formulary dynamics and tender outcomes, particularly for hospital procurement that operates on tight budget cycles. To mitigate these impacts, companies are adopting hedging strategies, renegotiating long-term supply agreements, and accelerating investments in modular manufacturing and regional production hubs that reduce dependence on tariff-affected trade lanes.

Integrated segmentation insights across product classes, administration routes, distribution pathways, and end user contexts to inform targeted commercialization and clinical adoption

A nuanced approach to segmentation yields actionable insights across product classes, routes of administration, distribution channels, and end user settings that collectively determine product positioning and commercialization strategy. Within product-based segmentation, bronchodilators remain foundational for symptomatic relief while combination products that pair long-acting bronchodilators with inhaled corticosteroids or other agents support broader control of airflow obstruction and exacerbation risk; antibiotics are deployed strategically for infectious exacerbations and mucolytics can improve sputum clearance for select patients. These distinctions require distinct evidence generation plans and patient support models to maximize therapeutic value.

Route of administration shapes both clinical outcomes and patient adoption. Inhalation continues to dominate given its direct effect on the airways, with dry powder inhalers, metered dose inhalers, and nebulizers each presenting tradeoffs in particle deposition, ease of use, and suitability for patients with limited inspiratory flow. Injectable routes are increasingly relevant for biologics targeting inflammatory pathways, while oral agents provide convenience and may complement inhaled therapy in specific cases. Distribution channel dynamics likewise influence access and adherence: hospital pharmacy procurement often prioritizes therapeutic equivalence and bulk availability, retail pharmacies deliver convenience for chronic dispensing, and online pharmacies are rising as an alternative for maintenance therapy, patient education, and adherence interventions. Finally, end user segmentation-comprising clinics, homecare environments, and hospitals-determines where resources for training, device support, and monitoring should be concentrated, as homecare expansion increases the need for remote support tools and simplified delivery systems.

Geographic intelligence highlighting distinct regulatory frameworks, payer dynamics, manufacturing capabilities, and patient access realities across major global regions

Regional dynamics continue to exert powerful influence on strategy, from regulatory pathways to patient access and device preferences. In the Americas, reimbursement mechanisms and a competitive branded and generic landscape drive rapid uptake of validated delivery technologies and digital adherence tools, while payer scrutiny necessitates robust health economic evidence for premium innovations. In Europe, Middle East & Africa, heterogeneous regulatory approaches and variable reimbursement environments favor flexible market entry strategies that combine local partnerships with regionally tailored pricing and access plans; here, device simplicity and cost-effectiveness frequently weigh heavily in procurement decisions.

Asia-Pacific presents a mosaic of advanced manufacturing capacity, growing demand, and intense competition from regional generic manufacturers; regulatory harmonization efforts in certain jurisdictions are accelerating approval for both inhaled therapies and biologics, yet country-level reimbursement remains a gating factor. Across all regions, demographic trends, urbanization, and rising awareness of chronic respiratory disease are increasing demand for integrated care pathways and patient-centric delivery models. As a result, companies must calibrate regional strategies that balance central research priorities with localized execution plans that account for regulatory nuance, payer behavior, and distribution infrastructure.

Strategic corporate landscape review describing how manufacturers and device partners are aligning development, partnerships, and evidence generation to differentiate COPD offerings

Leading pharmaceutical and device organizations are reorienting portfolios and partnerships to capture clinical differentiation and operational efficiencies in COPD therapeutics. Strategic priorities commonly include advancing device-drug combination platforms, investing in real-world evidence initiatives to substantiate outcomes in routine care, and forging collaborations with digital health firms to embed adherence and inhaler technique support into product value propositions. Contract manufacturing and specialty inhaler suppliers are gaining prominence as companies seek scalable, quality-compliant production to meet complex device assembly and delivery requirements.

Competitive differentiation increasingly rests on integrated offerings that combine optimized formulations with ergonomically designed delivery systems and patient support services. Companies pursuing biologics are aligning clinical development to specific inflammatory phenotypes while concurrently building payer dossiers that articulate long-term reductions in exacerbations and resource utilization. Smaller innovators focus on niche advantages such as ultra-fine particle delivery, propellant-free inhaler technology, or novel mucolytic chemistries, and they often partner with larger organizations for commercialization reach. Overall, corporate success depends on aligning scientific innovation with pragmatic manufacturing strategies and payer-engaged evidence generation.

Practical and prioritized recommendations for industry leaders to align product design, evidence generation, supply chain resilience, payer engagement, and patient support

Industry leaders should pursue a balanced strategy that links clinical differentiation to scalable commercial execution. First, prioritize device and formulation choices that directly address real-world adherence and technique barriers by emphasizing intuitive design, clear instructions, and integrated digital monitoring that drives actionable clinician insight. Concurrently, invest in targeted evidence generation that pairs traditional clinical endpoints with patient-reported outcomes and health economic models to speak directly to payer concerns about long-term value.

Second, strengthen supply chain resilience through diversified sourcing, regional manufacturing partnerships, and flexible contract manufacturing agreements that reduce exposure to tariff and trade disruptions. Third, adopt a patient-centric commercialization approach that extends beyond product launch to include remote support, education programs for clinics and homecare teams, and collaborations with pharmacy partners to streamline access and persistence. Finally, pursue selective strategic alliances-whether for biologic development, device innovation, or digital therapeutics-to accelerate time to market while preserving focus on core capabilities and regulatory compliance.

Transparent research methodology detailing primary stakeholder engagement, secondary literature synthesis, regulatory and patent intelligence, and expert validation processes

The research underpinning this report synthesizes primary and secondary evidence through a structured, multi-method approach. Primary research included qualitative interviews with clinicians, respiratory nurses, hospital pharmacists, payers, and industry executives to capture frontline perspectives on prescribing drivers, device preferences, and adoption barriers. These insights were complemented by targeted consultations with regulatory and reimbursement experts to illuminate approval pathways and payer decision criteria across geographies.

Secondary research encompassed systematic review of peer-reviewed clinical literature, clinical trial registries, regulatory guidance documents, and product labels to validate therapeutic mechanisms and safety profiles. Patent landscapes and scientific conference proceedings provided forward-looking signals about pipeline maturation. Throughout the process, findings were triangulated across data sources and subjected to expert validation workshops to refine conclusions and ensure practical relevance for commercial strategy and clinical translation.

Concluding synthesis emphasizing the necessity of integrated clinical differentiation, device innovation, evidence generation, and supply chain agility for sustained success

In summary, the COPD therapeutic landscape is defined by a convergence of clinical nuance, device evolution, and changing care delivery models that together demand integrated strategic responses. Stakeholders who align scientific innovation with patient-centric device design, robust real-world evidence, and resilient supply chains will be best positioned to navigate reimbursement scrutiny and competitive pressure. Transitioning from product-centric thinking to holistic care solutions-where delivery systems, digital support, and provider education form part of the therapeutic value proposition-will accelerate adoption and improve outcomes.

Looking forward, agility will be critical. Companies that proactively adapt to regional regulatory variation, tariff-related supply challenges, and evolving payer expectations can convert these potential headwinds into opportunities for differentiation. By centering decisions on demonstrable patient benefit and operational sustainability, organizations can both advance clinical care and achieve commercial success in a market that increasingly prizes measurable value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Product

  • 8.1. Antibiotics
  • 8.2. Bronchodilators
  • 8.3. Combination Products
  • 8.4. Corticosteroids
  • 8.5. Mucolytics

9. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Route Of Administration

  • 9.1. Inhalation
    • 9.1.1. Dry Powder Inhaler
    • 9.1.2. Metered Dose Inhaler
    • 9.1.3. Nebulizer
  • 9.2. Injectable
  • 9.3. Oral

10. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Chronic Obstructive Pulmonary Disease Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Homecare
  • 11.3. Hospitals

12. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Chronic Obstructive Pulmonary Disease Therapeutics Market

16. China Chronic Obstructive Pulmonary Disease Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Almirall S.A.
  • 17.7. Amgen Inc.
  • 17.8. Astellas Pharma Inc.
  • 17.9. AstraZeneca plc
  • 17.10. Aurobindo Pharma Ltd.
  • 17.11. Boehringer Ingelheim International GmbH
  • 17.12. Chiesi Farmaceutici S.p.A
  • 17.13. Cipla Limited
  • 17.14. CSL Limited
  • 17.15. Gilead Sciences, Inc.
  • 17.16. GlaxoSmithKline plc
  • 17.17. Glenmark Pharmaceuticals Ltd.
  • 17.18. Lupin Ltd.
  • 17.19. Mylan N.V.
  • 17.20. Novartis AG
  • 17.21. Orion Corporation
  • 17.22. Sandoz International GmbH
  • 17.23. Sun Pharmaceutical Industries Ltd
  • 17.24. Takeda Pharmaceutical Company Limited
  • 17.25. Teva Pharmaceutical Industries Ltd
  • 17.26. Theravance Biopharma, Inc.
  • 17.27. Verona Pharma plc
  • 17.28. Yuhan Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 116. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 118. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)